狼疮随机对照试验中特定器官领域测量:范围综述
结果显示94%的试验报告了至少一个器官领域的活动或反应,但器官特异性反应定义不一致,且多数器官领域的治疗组间比较受限于事后分析的小样本亚组。
要点
- SLE随机对照试验中黏膜皮肤和肌肉骨骼表现占主导,其他器官领域代表性低且变异大。
- 器官特异性反应定义不一致,即使在同一工具内也是如此。
- 需开发关键器官领域的新结局指标并验证比较现有反应定义。
核心结论
- SLE随机对照试验中器官特异性结局指标常被报告,但受累和反应的定义不一致。
- 黏膜皮肤和肌肉骨骼表现在SLE随机对照试验中占主导。
- 需要开发关键器官领域的新结局指标,并验证和比较现有工具的反应定义。
研究设计与样本
- 范围综述,检索MEDLINE、EMBASE、Cochrane注册库和clinicaltrials.gov。
- 纳入2000年1月至2021年3月发表的免疫导向药物治疗活动性SLE的随机对照试验,排除仅限狼疮肾炎的研究。
主要发现
- 研究人群基线肌肉骨骼和黏膜皮肤活动频率高但变异大,其他领域代表性低且变异大。
- 器官特异性反应定义不一致,即使在同一工具内也是如此。
- 大多数器官领域的反应使用BILAG和SLEDAI组分评估,但治疗组间有意义比较受限于事后分析的小样本亚组。
- 部分研究使用了特定的黏膜皮肤和关节炎工具,包括在预先指定的器官特异性终点中,这些工具在某些研究中能区分治疗组。
关键数值与推荐
- 器官特异性反应定义不一致,即使在同一工具内也是如此。
- 大多数器官领域的反应使用BILAG和SLEDAI组分评估。
临床怎么用
- 解读SLE随机对照试验时需注意器官特异性反应定义不一致的限制。
- 黏膜皮肤和关节炎的特定工具可在预先指定的器官特异性终点中区分治疗组。
局限性
- 器官领域的治疗组间比较受限于事后分析的小样本亚组。
- 器官特异性反应定义不一致,即使在同一工具内也是如此。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Randomized controlled trials (RCTs) in SLE (lupus) typically adopt composite responder definitions as primary efficacy endpoints; however, outcomes within individual organ domains are also important to understand. The aim of this scoping review was to evaluate how organ-specific disease activity and therapeutic responses have been measured and reported in lupus RCTs. METHODS: We searched MEDLINE, EMBASE, Cochrane registry and clinicaltrials.gov. Eligible studies were RCTs investigating efficacy of an immune-directed drug therapy in active SLE, published January 2000-March 2021, excluding studies limited to lupus nephritis. Data were extracted independently in duplicate into a template and summarized descriptively. RESULTS: Thirty-four RCTs were included, of which 32 (94%) reported activity and/or responses in at least one organ domain. Study populations had a high, although variable, frequency of baseline musculoskeletal and mucocutaneous activity and low, but also variable, representation of other domains. Definitions of organ-specific responses were inconsistent, even within individual instruments. Response in most organ domains were evaluated using BILAG and SLEDAI components but meaningful comparison between treatment arms was limited by small subgroups analysed in a post hoc fashion. Specific mucocutaneous and arthritis instruments were also used, including within pre-specified organ-specific endpoints, which discriminated between treatment arms in some studies. CONCLUSION: Mucocutaneous and musculoskeletal manifestations predominate in SLE RCTs. Organ-specific outcome measures are commonly reported, but definitions of involvement and response are inconsistent. Research into the development of new outcome measures for key organ domains, and validation and comparison of response definitions using existing instruments, is needed.
引用
- Connelly K, Vettivel J, Golder V, et al. Measurement of specific organ domains in lupus randomized controlled trials: a scoping review. Rheumatology (Oxford). 2022. PMID: 34664636. doi:10.1093/rheumatology/keab777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。